Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer - Wikidata - awgldk - TriplyDB

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer

http://www.wikidata.org/entity/Q33366785

about

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.

P2860

Q37113732-54635644-20F1-4C99-A0E7-8737AA136697 Q40109233-2307CA57-1D45-4F28-9C5F-2350E8D6BBEC

P2860

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer

http://www.wikidata.org/entity/Q33366785

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Pharmacokinetically guided pha ...... te in recurrent ovarian cancer

@ast

Pharmacokinetically guided pha ...... te in recurrent ovarian cancer

@en

type

label

Pharmacokinetically guided pha ...... te in recurrent ovarian cancer

@ast

Pharmacokinetically guided pha ...... te in recurrent ovarian cancer

@en

prefLabel

Pharmacokinetically guided pha ...... te in recurrent ovarian cancer

@ast

Pharmacokinetically guided pha ...... te in recurrent ovarian cancer

@en

P1433

Q33366785-3F12B01C-C0E2-494B-9336-D571EB399CD5

P1476

Q33366785-FEE5244A-BF8C-42E9-BD42-6EFA40CDFD01

P2093

Q33366785-5EFC0773-BF30-4F1B-8B4C-757CCFD90E25

Q33366785-64FC47E4-08E9-4836-AD25-4EB3AE00F11D

Q33366785-76AB42CF-B423-4694-A97E-055DD7B2F550

Q33366785-7EB515E3-39C5-4E8E-AF89-B506919525D0

Q33366785-84EF325D-FCB6-4D4B-B955-80FCD4216B12

Q33366785-8FA299F9-9E6E-4AA8-BBB5-09ABEDE5DE2A

Q33366785-B274D059-8B23-47B0-BE2E-91BA0B887E92

Q33366785-C0E342E5-604D-4909-8F61-FEA77A91BCE7

Q33366785-CC9E0A9A-C37D-4066-AE4E-4A6E2097DB8A

Q33366785-F6FC74FB-9E24-4D3C-B2B5-5E4C72285D23

P2860

Q33366785-01CB4B7A-6624-4040-8E4F-EF677B6C913C

Q33366785-0205651F-955A-421E-BA4D-D0BA5B410A73

Q33366785-04251B70-5047-4F67-AE27-AA9302256E59

Q33366785-0EA2ECA9-7201-4316-B921-2D2D96CB23AC

Q33366785-11C5438F-A3AE-4B28-8582-622E4D70FE30

Q33366785-1377B3DE-34E5-48D0-9596-B511784C5497

Q33366785-1DABE621-42E4-48F7-9789-81F3715C84AA

Q33366785-24C3B579-DA0A-4C11-8715-BF46D7D27B22

Q33366785-24E6B7A4-771E-4A4F-A9B1-119E9FF326F2

Q33366785-25A8CAE2-A597-45F4-A95E-60972CC4321A

P2888

Q33366785-682D56D7-724C-4285-B35A-9F23EB7D3BFD

P304

Q33366785-C6E306CA-F881-441B-B3C6-1650AF510E87

P31

Q33366785-6675D0ED-D768-44F4-83D8-09C9CAA42DD5

P356

Q33366785-621633FD-D819-4688-9B9F-5035839D78D8

P407

Q33366785-B3ACA461-15A4-4922-B164-2F4116F728A2

P433

Q33366785-9EF67D72-6298-4BB1-B780-96087E95E180

P478

Q33366785-DAF65A95-5A0E-4280-BDA8-5EBD2345735E

P50

Q33366785-D2211C96-97F8-4011-A0E3-69D266D6F1F8

P577

Q33366785-595483B3-6DCE-47B0-94CF-BCB83D2A0A3A

P5875

Q33366785-DB6678B9-7874-40AE-83B8-FC2910C215A4

P6179

Q33366785-3DD6C1CA-F37B-43B8-889D-92049E08FBD3

P698

Q33366785-8E1938EC-74C4-4A94-AC77-5C60C9AA21AD

P921

Q33366785-1CFCCD38-02CC-4495-B7DB-01753F469BFC

Q33366785-64408B59-C438-4BD3-8382-4FC4A5803F9A

P932

Q33366785-5404849C-0BD9-4A74-A338-F2E3650657CC

P356

P1433

British Journal of Cancer

P1476

Pharmacokinetically guided pha ...... te in recurrent ovarian cancer

@en

P2093

C Echeta

http://www.w3.org/2001/XMLSchema#string

D J Propper

http://www.w3.org/2001/XMLSchema#string

E Flanagan

http://www.w3.org/2001/XMLSchema#string

I D Hickson

http://www.w3.org/2001/XMLSchema#string

J P Braybrooke

http://www.w3.org/2001/XMLSchema#string

N C Levitt

http://www.w3.org/2001/XMLSchema#string

R Te Poele

http://www.w3.org/2001/XMLSchema#string

S Joel

http://www.w3.org/2001/XMLSchema#string

S L Davies

http://www.w3.org/2001/XMLSchema#string

T S Ganesan

http://www.w3.org/2001/XMLSchema#string

P2860

Etoposide: four decades of development of a topoisomerase II inhibitor

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.

A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer.

A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients.

A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.

Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.

Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

P2888

P304

60-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6602657

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P50

Srinivasan Madhusudan

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7785801

http://www.w3.org/2001/XMLSchema#string

P6179

1011392510

http://www.w3.org/2001/XMLSchema#string

P698

15956976

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2361471

http://www.w3.org/2001/XMLSchema#string